Ramucirumab - Biologic Drug Details

Summary for ramucirumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ramucirumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ramucirumab

Recent Clinical Trials for ramucirumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jeeyun Lee	Phase 1/Phase 2
Jazz Pharmaceuticals	Phase 2
Canadian Cancer Trials Group	Phase 2

See all ramucirumab clinical trials

Pharmacology for ramucirumab

Mechanism of Action	VEGFR2 Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Receptor 2 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ramucirumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ramucirumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ramucirumab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Ramucirumab

Market Overview

Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), is a crucial component in the treatment of various cancers, including colorectal, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and advanced or metastatic gastric cancer. Here’s a detailed look at the market dynamics and financial trajectory of this biologic drug.

Growth Rate and Market Size

The global Ramucirumab market is anticipated to grow at a compound annual growth rate (CAGR) of around 4.8% from 2024 to 2031, with the market size expected to increase from USD 1.23 billion in 2023 to USD 1.79 billion by 2031[3].

Key Drivers

Increasing Incidence of Cancer

The rising prevalence of malignancies such as gastric, colorectal, NSCLC, and HCC is a significant driver for the Ramucirumab market. The growing need for effective treatments for these cancers fuels the demand for Ramucirumab[1][3].

Regulatory Approvals and Expanding Indications

Ramucirumab has received regulatory approvals for various indications, including second-line treatments for gastric and NSCLC. These approvals, along with ongoing clinical research, are expanding its potential applications and market share[1][3].

Combination Therapies

The drug is often used in combination with other chemotherapy agents like FOLFIRI, Paclitaxel, or Docetaxel. Combination therapies have shown higher efficacy and are more widely adopted, contributing significantly to the market growth[1].

Healthcare Infrastructure and Awareness

Improvements in healthcare infrastructure, especially in developing regions, and increasing cancer awareness are facilitating market expansion. Strategic alliances, early diagnosis, and favorable reimbursement schemes also play a crucial role[1].

Regional Market Analysis

North America

North America dominates the Ramucirumab market, driven by its advanced healthcare infrastructure, high cancer prevalence, and substantial investment in research and development. The region's well-established healthcare system and strong emphasis on innovative therapies contribute to robust market growth[1].

Europe

Europe's market benefits from well-established healthcare systems and a supportive regulatory environment, including endorsements from the European Medicines Agency. Countries like Germany, France, and the UK are key contributors due to their strong healthcare infrastructure and funding[1].

Asia-Pacific

The Asia-Pacific region is experiencing rapid growth due to rising cancer rates and improving healthcare infrastructure. Economic development and increasing cancer incidence in this region are driving the demand for Ramucirumab[1].

Market Segmentation

By Application

The Ramucirumab market is segmented into monotherapy and combination therapy, with combination therapy accounting for the largest share, around 85% in 2024. This is due to the higher efficacy and broader range of applications of combination treatments[1].

By Product

The market is also segmented by product form, including injections, infusions, vials, single-dose, multi-dose, and pre-filled syringes. These various forms cater to different clinical needs and preferences[3].

Financial Trajectory

Cost-Effectiveness Analysis

A cost-effectiveness analysis of Ramucirumab plus erlotinib compared to placebo plus erlotinib in the first-line setting for NSCLC patients showed that while the combination therapy provided additional quality-adjusted life years (QALYs), it came at a significant cost. The incremental cost-effectiveness ratio (ICER) was $128,302/QALY, which is not cost-effective in many regions unless the price of Ramucirumab is reduced substantially[2].

Revenue Projections

The global Ramucirumab market is projected to grow significantly, driven by the increasing demand for targeted cancer therapies. The revenue is expected to reach USD 1.79 billion by 2031, up from USD 1.23 billion in 2023[3].

Competitive Landscape

The market is characterized by a competitive landscape with several key players. The report includes a Porter’s Five Forces analysis, which examines the bargaining power of buyers and suppliers, the threat of new entrants, the threat of substitutes, and the degree of competition in the market[3].

Challenges and Opportunities

Pricing and Reimbursement

One of the significant challenges is the high cost of Ramucirumab, which affects its cost-effectiveness. Price reductions through negotiations with healthcare authorities can improve its cost-effectiveness and market adoption[2].

Clinical Research and Development

Ongoing clinical research and the emergence of new combination therapies offer opportunities for market growth. Advances in oncology and the expanding range of indications for Ramucirumab are expected to drive its market potential[1][3].

Regulatory Environment

A supportive regulatory environment, including approvals from agencies like the European Medicines Agency, is crucial for the market expansion of Ramucirumab. Favorable regulatory conditions can accelerate the adoption of new treatments[1].

Key Takeaways

• Growth Rate: The Ramucirumab market is expected to grow at a CAGR of around 4.8% from 2024 to 2031.
• Market Size: The market is projected to reach USD 1.79 billion by 2031.
• Key Drivers: Increasing cancer incidence, regulatory approvals, and combination therapies are driving the market.
• Regional Dominance: North America leads the market, followed by Europe and the Asia-Pacific region.
• Cost-Effectiveness: The drug's high cost is a challenge, but price reductions can improve its cost-effectiveness.

FAQs

What is Ramucirumab used for?

Ramucirumab is used to treat various cancers, including colorectal cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and advanced or metastatic gastric cancer.

What is the expected growth rate of the Ramucirumab market?

The Ramucirumab market is expected to grow at a CAGR of around 4.8% from 2024 to 2031.

Which region dominates the Ramucirumab market?

North America dominates the Ramucirumab market due to its advanced healthcare infrastructure and high cancer prevalence.

What are the key drivers of the Ramucirumab market?

Key drivers include the increasing incidence of cancer, regulatory approvals for various indications, and the use of combination therapies.

Is Ramucirumab cost-effective?

Ramucirumab's cost-effectiveness is a challenge due to its high price. However, price reductions through negotiations can improve its cost-effectiveness.

Sources

1. We Market Research: Global Ramucirumab Market Size, Share, Trends & Statistics 2034[1]
2. BMJ Open: Cost-effectiveness analysis of adding ramucirumab to the first-line setting for NSCLC patients[2]
3. Market Research Intellect: Ramucirumab Market Size and Projections[3]
4. Cognitive Market Research: Ramucirumab Market Report 2024 (Global Edition)[4]

Last updated: 2024-12-17